Net Sales are expected to decrease by 3.5 percent Y-o-Y (down 7.3 percent Q-o-Q) to Rs. 3,430 crore, according to PL Capital.
Net Sales are expected to decrease by 13.5 percent Y-o-Y (down 2.8 percent Q-o-Q) to Rs. 99,940 crore, according to PL Capital.
Cipla's US sales are expected to be adversely impacted by price erosion and supply disruptions for tumor drug Lanreotide, capping revenue growth.
Net Sales are expected to increase by 2.1 percent Y-o-Y (down 0.3 percent Q-o-Q) to Rs. 1,176.3 crore, according to PL Capital.
Net Sales are expected to increase by 0.3 percent Y-o-Y (up 14.9 percent Q-o-Q) to Rs. 387 crore, according to PL Capital.
Net Sales are expected to decrease by 2.8 percent Y-o-Y (up 19.7 percent Q-o-Q) to Rs. 991.6 crore, according to PL Capital.
Net Sales are expected to increase by 6.9 percent Y-o-Y (up 6.9 percent Q-o-Q) to Rs. 1,464.9 crore, according to PL Capital.
Analysts anticipate lower sales of blockbuster cancer drug Revlimid to squeeze Dr Reddy's margins for Q3, thereby dragging earnings growth.
According to a Moneycontrol poll of nine brokerages, Hindustan Unilever's net profit for the quarter is likely to come in at Rs 2,587 crore.
Net Sales are expected to increase by 16.5 percent Y-o-Y (up 4.3 percent Q-o-Q) to Rs. 38,795.3 crore, according to PL Capital.
Net Sales are expected to increase by 23.4 percent Y-o-Y (up 13.3 percent Q-o-Q) to Rs. 31,204.2 crore, according to PL Capital.
Net Sales are expected to increase by 2.8 percent Y-o-Y (down 4.5 percent Q-o-Q) to Rs. 9,993.2 crore, according to PL Capital.
Net Sales are expected to increase by 21.8 percent Y-o-Y (up 19.3 percent Q-o-Q) to Rs. 5,087.9 crore, according to PL Capital.
Net Sales are expected to increase by 6 percent Y-o-Y (down 4.6 percent Q-o-Q) to Rs. 4,071 crore, according to PL Capital.
Net Sales are expected to increase by 8 percent Y-o-Y (down 0.3 percent Q-o-Q) to Rs. 13,084.4 crore, according to PL Capital.
Net Sales are expected to increase by 13.2 percent Y-o-Y (up 18.7 percent Q-o-Q) to Rs. 43,768 crore, according to PL Capital.
Net Sales are expected to decrease by 0.9 percent Y-o-Y (up 4.8 percent Q-o-Q) to Rs. 9,187.3 crore, according to PL Capital.
Net Sales are expected to increase by 15.5 percent Y-o-Y (up 5.5 percent Q-o-Q) to Rs. 43,764.9 crore, according to PL Capital.
Among the brokerages polled, Axis Securities rolled out the most bullish projections while B&K Securities forecasted the slowest revenue and PAT growth for UltraTech Cement.
Brokerages hold differing views on the impact of Wipro's wage hikes on its EBIT margins in Q3. While some predict a slight decline in margins, others believe strong cost optimisation measures will offset the impact. Wipro implemented the wage hike in early September.
Tech Mahindra's net profit is anticipated to decline sequentially due to a high base, while weak seasonality and increased furloughs are expected to limit revenue growth.
Axis Bank's NII will likely reach Rs 13,794 crore in Q3FY25 while net profit is expected to rise to Rs 6,416 crore
All eyes are on whether Infosys will raise or narrow its full-year revenue guidance as most analysts either expect an increase in guidance or narrowing of the guidance band.
HDFC Life's APE is expected to rise to Rs 3,626 crore for the quarter ended December 2024, while VNB is likely to grow to Rs 908 crore
As Q3 growth outperformance expectations grow louder, investors eagerly await potential upward revisions in HCLTech's growth guidance.